We are thrilled to announce that we will be co-hosting July 9th Biotech Tuesday! We look forward to making new connections, see you there! For more information or to purchase tickets go to: https://lnkd.in/gjMwe35n
Join us for Triangle Biotech Tuesday. https://lnkd.in/gjMwe35n
Senior Recruitment Consultant & Executive Headhunter - Seven Life Sciences & Seven Executive.
🔬 Exciting insights from Labiotech.eu on the top 10 pharma and biotech venture capital arms! These VC arms are driving innovation by investing in transformative therapeutics and cutting-edge technologies. Highlights include AbbVie Ventures' focus on oncology and neuroscience, JJDC's broad pharmaceutical and medtech investments, and Leaps by Bayer's mission to tackle global challenges. Other key players like Pfizer Ventures and Novartis Venture Fund are also making significant contributions to the biotech ecosystem. Read more to discover how these firms are shaping the future of healthcare and biotechnology: https://lnkd.in/eBF5Xx8w 🚀💡
Today's the day. Check out my presentation at Fierce Biotech JPM week on success factors for the biotech company journey from discovery to commercialization. You can register here. https://lnkd.in/eQTYR4nE
Learn more about drug discovery assays and how Momentum can help your research!
Learn something new! Come join us for a C&EN webinar sponsored by Momentum Biotechnologies. https://lnkd.in/en-xuNTu
🔬 Curious about the current state of the biotech market? 📈 Wondering how investor sentiment is evolving and what factors are influencing investment decisions? 🌍 Interested in understanding the geopolitical and economic factors impacting the global biotech landscape? These are the questions I frequently get asked by clients across the biopharma sector. As part of the LifeSci Partners platform, I'm fortunate to have access to a wealth of knowledge and insights from colleagues who closely monitor market dynamics, enabling us to provide informed guidance to biopharma companies. 🎯 For those seeking a regular, thorough, and insightful overview of the biotech market, I highly recommend tuning into LifeSci Capital LLC's monthly Biotech Capital Markets Update. This interactive discussion delves into the current state of the biotechnology markets, offering valuable insights on financing dynamics within the healthcare sector. #biotech #capitalmarkets #lifesciences #marketintelligence #healthcarefinance
Tune in LIVE on Wednesday, Feb. 21 at 11am ET for our monthly Biotech Capital Markets Update, featuring an interactive and informative discussion moderated by Hany Awadalla and Mark Charest, Ph.D. on the current state of the biotechnology markets, incorporating relevant insights on the financing environment in the healthcare sector. Register here: https://brnw.ch/21wGLet
BCBN Feed: STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch https://lnkd.in/g5sSrkdC Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter. ... [...]
Duration is the major driver of cost for clinical trials. Optimising your development timelines, including efficient engagement with regulators, can significantly benefit scare budget allocation. Get advice and insights from our biotech experts by downloading our biotech funding whitepaper series here: https://ow.ly/pS4y50RrYpV
📈💡 Is Soligenix (SNGX) the next big winner in biotech? Find out in our latest video! 🚀🔬 We dive deep into their HyBryte study and explore the future potential of this innovative biopharmaceutical company. Discover Soligenix's recent achievements, upcoming milestones, and what makes HyBryte a standout treatment in the biotech landscape. Join us as we analyze the key factors driving Soligenix's growth and see if SNGX stock is a smart investment for the future. 📊💰 Watch the Full video: https://lnkd.in/d79dTF_d
Even with more financing available, early-stage biotech companies have to fight harder for their share of funding. We explore the challenges, strategies, and best practices in early-stage biotech funding: https://hubs.la/Q02rz40T0
Spotlight on BIO-Europe: We spoke to Elisabeth Lackner, member of the supervisory board of Marinomed Biotech AG, who talked about their partnering strategy. With an antiviral #Carragelose business, Marinosolv assets in Phase 3 and 2 for immunological indications, and their Solv4U platform that supports partners with solubilization of their product candidates, Marinomed certainly had a busy BIO-Europe. Watch the video below or directly on our YouTube channel where you can also find more highlights of the conference 👉 : https://bit.ly/477gOeI #bioeurope #bioeurope2023 #BiotechInvestment #HealthcareInnovation
Dimerix Limited (ASX:DXB, OTC:SBMJF) CEO and managing director Dr Nina Webster is in the Proactive studio following the 18th annual Bioshares Biotech Summit in Perth. Dimerix is is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Incorporated in 2004, Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using its innovative receptor technology to identify and develop drugs in areas with an unmet need. Dimerix has successfully used the Receptor-HIT technology to identify a novel treatment (DMX-200) that may transform the lives of patients with #InflammatoryDiseases, such as kidney or lung diseases. Dimerix encourages collaboration and is well positioned to discuss partnering and product development. Watch at #Proactive #ProactiveInvestors #KidneyDisease #LungDisease #Biotech #Biopharmaceutcials Elisha Newell https://lnkd.in/eMT7kHqg
